ABSTRACT
Development in the areas of anticoagulants, platelet inhibitors, and fibrinolytics has continued with the growth in the number of patients with diseases complicated by thrombosis. New groups of therapeutics are being developed, while existing therapies are being further studied for expanding indications, beneficial combinations, and optimized dosing. In addition, therapies are being explored utilizing evolving techniques in the fields of proteomics and transciptomics. Much of the recent excitement has been centered on the potential for individual and targeted dosing in the use of anticoagulants and other antithrombotics. All of these goals hold the promise of diminished side effects and complications, particularly with bleeding.
